2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
2 citations
,
July 2022 in “Sexual Medicine” Certain medications, especially 5-α reductase inhibitors and neuropsychiatric drugs, are often linked to erectile dysfunction.
June 2018 in “Evidence-Based Practice” Finasteride can double the risk of sexual problems like ejaculation issues, low libido, and impotence.
1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” The new compound may be a safer alternative to finasteride for prostate protection.
21 citations
,
January 2017 in “Dermatology Online Journal” Finasteride and dutasteride can cause sexual problems like impotence and low libido.
3 citations
,
January 2015 in “Journal of drug assessment” Taking five small dutasteride capsules is the same as taking one larger capsule.
15 citations
,
July 2019 in “Journal of Biological Inorganic Chemistry” Finasteride helps prevent kidney stones, but side effects need more research.
Testosterone, 4-hydroxyandrostenedione, and finasteride affect blood clotting differently in stressed heart conditions.
3 citations
,
October 2018 in “Experimental and Therapeutic Medicine” Stopping tamsulosin one month before cataract surgery reduces eye surgery complications in rats.
4 citations
,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
January 2004 in “Chinese Journal of New Drugs and Clinical Remedies” The two finasteride tablet brands are bioequivalent.
14 citations
,
January 2003 in “Actas Urológicas Españolas” Finasteride effectively reduces symptoms of enlarged prostate with minimal side effects.
February 2023 in “Sexual Medicine Reviews”
October 2010 in “Journal of Men's Health” The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
March 2005 in “The Nurse Practitioner”
1 citations
,
September 2016 in “Acta Chromatographica” Created method to measure doxazosin mesylate and finasteride together.
2 citations
,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
July 2012 in “Reactions Weekly” Crushed finasteride tablets can harm pregnant and fertile women.
13 citations
,
September 2011 in “International Urology and Nephrology”
69 citations
,
July 2015 in “Pharmacotherapy” Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.
The combined treatment of Finasteride and Doxazosin affects prostate tissue by reducing cell growth and altering hormone levels.
January 2018 in “Surgical and Cosmetic Dermatology” Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
December 2010 in “Actas Urológicas Españolas” Taking dutasteride for one month before prostate surgery can reduce bleeding.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
26 citations
,
July 2014 in “Analytical Chemistry Research” Method can accurately measure five BPH drugs at once.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
January 2016 in “ISBN: 978-84-608-9184-0”